Plné znění - 163/2026 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

163/2026 Sb.
 

Sdělení Ministerstva zahraničních věcí

INFORMACE

163

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx mění x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 58/2007 Xx. x. x. x č. 46/2008 Xx. x. x.

Xxxxxxxxxxxx zahraničních věcí xxxxxxx, že xxx 15. xxxxxxxxx 2024 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx znění Přílohy I - Xxxxxx xxxxxxxxxx xxxxx a metod xxxxxxx xxx xxx 2025 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx.

X xxxxx zněním Přílohy I xxxxxxxx xxxxxxx Xxxxxxxxx České xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx xxxx Přílohy I Xxxxxx xxxxxxxxxx.

Xxxx znění Xxxxxxx I xxxxxxxxx x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Úmluvy xxx 1. xxxxx 2025, xxx Xxxxxx xxxxxxxxx vstoupilo v xxxxxxxx dne 15. xxxx 2025 a xxxxxxxxx Přílohu I xxx xxx 2024, platnou xx 1. xxxxx 2024, xxxxx vstoupila x xxxxxxxx xxx Xxxxxx republiku xxx 18. xxxxxx 2024 x xxxx vyhlášena xxx č. 19/2025 Sb.

Xxxxxxxx znění Přílohy I pro xxx 2025 a xxxx xxxxxxx do českého xxxxxx xx vyhlašují xxxxxxxx.

Xxxxxxx:

x x. Xxx. Xxxxx v. r.

vrchní xxxxxxx xxxxx xxxxxx x xxxxxxxxxx
&xxxx;

Xxxx

Xxxxxx xxxxxxxxxx xxxxx x metod xx xxxxxxx Xxxxxxxxxxx xxxxxxxx v xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx programu.

Seznam xx xxxxxxxxxx aktualizován xx xxxxxxxxx konzultačním xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx agenturou (XXXX). Xxxxxx xx xxxxxx xx 1. ledna 2025.

Xxxxxxxxx xxxx Seznamu xxxxxxxxxx látek x xxxxx xxxx xxxxxxxxx XXXX a xxxx xxxxxxxxxx v angličtině x xxxxxxxxxxxxx. V xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxx xxxxxxxxx xxxxx x xxxxxxxxxx.

Xxxx xxxx xxxxxxx xxxxxxx xxxxx xxxxxxxxx x xxxxx Xxxxxxx zakázaných xxxxx x xxxxx.

Xxxxxxxx Xxx xxxxxxx

Xxxxx XXXX xxx xxxx sport xxxxxxxxxxx jiné období, xx období Xxx xxxxxxx x xxxxxx xxxxxxx začínajícím xxxxx xxxx xxxxxxx (xx 23:59 hodin) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx xx má Xxxxxxxxx xxxxxxxxx, xx xx xxxxx Xxxxxxx x procesu xxxxxx Xxxxxx.

Xxxxxxxx xxxxx

Xx znamená, xx xxxx xxxxx xxxx metoda je xxxxxxxx Xxx xxxxxxx x Xxxx soutěž, xxx je xxxxxxxxxx x Xxxxxx.

Xxxxxxxxxx x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Xxxxxx „xxx xxxxx xxxxxxxx xxxxxx 10 budou xxxxxxx Xxxxxxxx xxxxx Xxxxxxxxxxxx xxxxxxx, x xxxxxxxx xxxx označených x Xxxxxxx zakázaných xxxxx x metod. Xxxxx Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx metodou, xxxxx xxxx x Xxxxxxx xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx metoda“. Xxxxx xxxxxxxxx k xxxxxx „Xxxxxxxxxx xxxxx x Xxxxxxxxxx xxxxxx xxxxxxx x xxxxxx 4.2.2 xx xxxxxx xxx xxxxxx způsobem xxxxxxxxxx xx xxxx xxxxxxxx nebo xxxx xxxxxxxxxx xxx xxxx xxxxxxxxx látky nebo xxxxxx. Jde xxxxx x xxxxx a xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx užil nebo xxxxxx x jinému xxxxx než xx xxxxxxxx xxxxxxxxxxx xxxxxx.“

Xxxxxxxx xxxxx

Xxxxx článku 4.2.3 Xxxxxx xxxx Návykové xxxxx definovány xxxx xxxxx, které xxxx xxxx xxxxxx označeny x důvodu xxxxxx xxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxx xxxxxx. Jako Xxxxxxxx xxxxx xxxx xxxxxxxxxx xxxx xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 XXXXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxxxxxxx farmakologická xxxxx, xx xxxxxx xx xxxxxxxxxx žádný x xxxxxxxxxxxxx xxxxxx Seznamu x xxxxx není x xxxxxxxx době xxxxxxxxx žádným xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx orgánem xxx léčebné xxxxxxx x xxxx (xxxx. xxxxxx v xxxxxxxxxxxxx xxxx klinickém vývoji xxxx xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxx xxxxxx, látky xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxx xxxxxxxx.

Xxxx xxxxx xxxxxxxx xxxxx xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (DNP), stabilizátory xxxxxxxx xxxxxxxxxxxxx xxxxxxxxx-1-xxxxxxxxxx [xxxx. X-107, X48168 (XXX210)] a xxxxxxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx x xxxxxxxxxx).

X1 ANABOLICKÉ XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx zakázané xxxxx x této xxxxx xxxx Xxxxxxxxxxxx látky.

Anabolické xxxxx jsou zakázány.

S1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)

Xxx exogenním xxxxxx, xxxx xxxx xxxxxx:

•	1-xxxxxxxxxxxxxx (5ɑ -xxxxxxx-1-xx-3ß, 17ß-xxxx)		•	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ -androst-1-en-3, 17-xxxx)		•	xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)
•	1-xxxxxxxxxxx (3ɑ -xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-hydroxy-5ɑ-androst-1-en-17-on)		•	mestanolon
•	1-testosteron (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)		•	xxxxxxxxxx
•	4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx)		•	xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)
•	4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)		•	xxxxxxxxx
•	5-xxxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)		•	xxxxxxxxxx
•	7ɑ-xxxxxxx-XXXX		•	xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		•	xxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17ɑ-metyl-5ɑ-androst-1-en-3-on)
•	7-keto-DHEA		•	metylklostebol
•	11ß-metyl-19-nortestosteron		•	metyldienolon (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)
•	17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)		•	xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on)
•	19-norandrostenediol (xxxx-4-xx-3,17-xxxx)		•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (estr-4-en-3,17-dion)		•	metribolon (metyltrienolon, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	Xxxxxxx-4-xx-3,11,17-xxxxx (11-xxxxxxxxxxxxxxxxx, adrenosteron)		•	miboleron
•	androstanolon (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)		•	xxxxxxxxx (19-nortestosteron)
•	androstenediol (xxxxxxx-5-xx-3ß,17ß-xxxx)		•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx)		•	xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxx
•	xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		•	xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3β-hydroxyandrost-5-en-17-on)
•	dehydrochlormetyltestosteron (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)		•	xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- ol)		•	quinbolon
•	dimetandrolon (7ɑ,11ß-dimetyl-19-nortestosteron)		•	stanozolol
•	drostanolon		•	stenbolon
•	epiandrosteron (3β-xxxxxxx-5α-xxxxxxxxx-17-xx)		•	xxxxxxxxxxx
•	xxx-xxxxxxxxxxxxxxxxxx (17β-hydroxy-5β-androstan-3-on)		•	tetrahydrogestrinon (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx)		•	xxxxxxxxx (17β-hydroxyestr-4,9,11-trien-3-on)
•	fluoxymesteron		•	trestolon (7ɑ-metyl-19-nortestosteron, XXXX)

x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X1.2. OSTATNÍ XXXXXXXXXX LÁTKY

Mimo jiné xxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. xxxxxxx, xxxxxxxxx (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], xxxxxxx x xxxxxxxxxx.

X2 XXXXXXXXX HORMONY, RŮSTOVÉ XXXXXXX, PŘÍBUZNÉ XXXXX X XXXXXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxx v xxxx xxxxx xxxx Nespecifické xxxxx.

Xxxxxxxxxxx xxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx zakázány.

S2.1. XXXXXXXXXXXXX (XXX) X XXXXX XXXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx xxxxxx:

X2.1.1&xxxx;Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, např. darbepoetiny (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx založené xx XXX, [např. EPO-Fc, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA)]; XXX-xxxxxxxxx prostředky x xxxxxx xxxxxxxxxx, např. XXXX-530, peginesatid.

S2.1.2 Aktivační prostředky xxxxxxx xxxxxxxxxxxxxx faktoru (XXX), např. kobalt; xxxxxxxxxxx (XXX1278863); IOX2; xxxxxxxxxx (XXX 85-3934); xxxxxxxxxx (FG-4592); xxxxxxxxxx (XXX-6548); xxxxx.

X2.1.3&xxxx;Xxxxxxxxxx XXXX, xxxx. X-11706.

X2.1.4&xxxx;Xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX-β), xxxx. xxxxxxxxxxxx; sotatercept.

S2.1.5 Agonisté xxxxxxxxx xxxxxxxxx receptoru, xxxx. xxxxxx XXX; karbamylovaný XXX (XXXX).

X2.2. XXXXXXXXX XXXXXXX A XXXXXX XXXXXXXXXX XXXXXXX

X2.2.1&xxxx;Xxxxxxx stimulující xxxxxxxxxxx u xxxx, xxxx xxxx včetně:

• xxxxxxxx xxxxxxxxxxxx (XX),

• xxxxxxxxxxxx xxxxxx (LH),

• xxxxxx uvolňující xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) x xxxx xxxxxxxxxxx xxxxxxx (xxxx. buserelin, deslorelin, xxxxxxxxx, histrelin, leuprorelin, xxxxxxxxx x xxxxxxxxxxx),

• xxxxxxxxxx x jeho xxxxxxxxxxx analogy.

S2.2.2 Kortikotropiny x xxxxxx uvolňující faktory, xxxx. kortikorelin x xxxxxxxxxxxxx.

X2.2.3&xxxx;Xxxxxxx xxxxxx (XX), xxxx xxxxxxx a xxxxxxxxx, mimo xxxx xxxxxx:

• xxxxxxx xxxxxxxxx xxxxxxx, např. lonapegsomatropin, xxxxxxxxxxx a xxxxxxxxxx,

• xxxxxxxxx růstového xxxxxxx, xxxx. XXX-9604 x xXX 176-191.

X2.2.4&xxxx;Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, mimo xxxx xxxxxx:

• xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (XXXX) x xxxx xxxxxxx, xxxx. CJC-1293, XXX-1295, xxxxxxxxxx x xxxxxxxxxxx,

• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) a xxxxxx xxxxxxxx [např. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (XX-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx a xxxxxxxxxxx],

• peptidy xxxxxxxxxx XX (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (hexarelin), XXXX-1, XXXX-2 (pralmorelin), XXXX-3, XXXX-4, XXXX-5 x GHRP-6].

S2.3. RŮSTOVÉ XXXXXXX X MODULÁTORY XXXXXXXXX FAKTORŮ

Mimo xxxx xxxxxx:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (FGF)

• xxxxxxxxxxxx xxxxxxx faktor (XXX)

• xxxxxxx faktor 1 xxxxxxx xxxxxxxx (XXX-1, xxxxxxxxxx) x jeho xxxxxxx

• xxxxxxxxxx xxxxxxx xxxxxxx (MGF)

• xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX)

• xxxxxxxx-β4 x jeho xxxxxxxx, xxxx. TB-500

• xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (XXXX)

x xxxxx xxxxxxx xxxxxxx nebo xxxxxxxxxx xxxxxxxxx xxxxxxx ovlivňující xxxxxxx/xxxxxxxxx proteinů xx xxxxxxx, šlachách xxxx xxxxxx, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, regenerativní kapacitu xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3 XXXX-2 XXXXXXXX

XXXXXXXX STÁLE (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx xxxx-2 agonisté včetně xxxxx xxxxxxxxx izomerů xxxx zakázáni.

Mimo xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1 600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx po xxxxxxxxx xxxxx;

• xxxxxxxxx xxxxxxxxxx: maximální xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 36 xxxxxxxxxx xxxxx 12 xxxxx xx xxxxxxxxx dávce;

• xxxxxxxxx salmeterol: xxxxxxxxx 200 xxxxxxxxxx za 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 25 xxxxxxxxxx xx 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx salbutamolu x xxxx x xxxxxxxx xxxxxx než 1 000 xx/xx xxxx xxxxxxxxxxx x množství xxxxxx xxx 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx xxxxx x xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález (XXX), xxxxx Sportovec xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, že xxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx xxxxx (inhalační) xx do xxxx xxxxxxx maximální xxxxx.

X4 XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxxx látky xx xxxxxxx X4.1 x X4.2 jsou Xxxxxxxxxx xxxxx.

Xxxxx xxxxxxxx xx xxxx S4.3 a X4.4 xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.

X4.1. XXXXXXXXXX XXXXXXXX

Xxxx xxxx včetně:

•	2-androstenol (5ɑ-androst-2-en-17-ol)		•	androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-3,5-xxxx-7,17-xxxx (arimistan)
•	3-androstenol (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-androst-3-en-17-on)		•	formestan
•	4-androsten-3,6,17 trion (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXX (XXXXX)]

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXX XXX

Xxxx xxxx včetně:

•	protilátky xxxxxxxxxxxxxx xxxxxxx X		•	xxxxxxxxxx xxxxxxxxxx, xxxx.:
•	xxxxxxxxxx receptoru xxxxxxxx XXX, xxxx.:			- xxxxx xxxxxxxxx nebo rušící xxxxxxx myostatinu
	- xxxxxxx xxxxxxxxx xxxxxxxx (např. XXX-031)			- proteiny xxxxxx xxxxxxxxx (např. follistatin, xxxxxxxxx xxxxxxxxxx)
•	xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx IIB (xxxx. xxxxxxxxxx)			- xxxxxxxxxx xxxxxxxxxxxxxx myostatin nebo xxxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxx zumab, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. METABOLICKÉ XXXXXXXXXX

X4.4.1

• xxxxxxxxxx XXX-xxxxxxxxxx proteinkinázy (XXXX), xxxx. AICAR, xxxxxxxxxxxxxxx xxxxxxxx xxxxx xxxxx 12X xXXX-x (XXXX-x);

• xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx aktivovaného xxxxxxxxx xxxxx (XXXXδ), xxxx. 2-(2-xxxxxx- 4-((4-xxxxxx-2-(4-(xxxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (GW1516, XX501516) x;

• agonisté Rev-erbɑ, xxxx. SR9009, XX9011

X4.4.2 xxxxxxxx x xxxxxxxx xxxxxxxx, xxxx. X519, X597

X4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX X MASKOVACÍ XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX I MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické látky.

Všechna xxxxxxxxx x maskovací xxxxx, xxxxxx xxxxx xxxxxxxxx izomerů, xxxx. x- x l-, xxxx xxxxxxxx.

Xxxx jiné xxxxxx:

• Diuretika, jako xxxx.:

Xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxx; xxxxxxxxxxxx; kyselina xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx, xxxx. bendroflumethiazid, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxx;

• Xxxxxxx, xxxx. konivaptan, xxxxxxxxxx, xxxxxxxxx;

• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, xxxx.:

xxxxxxx, xxxxxxx, hydroxyetyl xxxxx, xxxxxxxx;

• Xxxxxxxxxxx;

• Xxxxxxxxxx;

x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými biologickými xxxxxx.

XXXXXXX

• xxxxxxxxxxx; pamabrom; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx karboanhydrázy (xxxx. dorzolamid, xxxxxxxxxxx);

• xxxxxxx xxxxxx xxxxxxxxxxx x zubní xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx množství látky xx xxxxxxxxxx prahovým xxxxxxx: u formoterolu, xxxxxxxxxxx, katinu, xxxxxxxx, xxxxxxxxxxxxx x pseudoefedrinu xx Vzorku Sportovce xxxxxxxx nebo xxxxxxxx Xxx Soutěži ve xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (kromě xxxxxxxxx xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxx lokálního xxxxxx felypresinu v xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález (AAF), xxxxx Sportovec xxxx xxxxxxxxxx Xxxxxxxxxxxxx výjimku (XX) xx xxxx xxxxx xxxxx k xx, která xxx xxxx xxxxxxx na xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxxx x xxxx třídě jsou Xxxxxxxxxxxx s výjimkou xxxxx x M2.2, xxx xxxx Xxxxxxxxxx xxxxxx.

X1. XXXXXXXXXX S XXXX A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X1.1. Xxxxxx xxxx xxxxxxxx xxxxxxxx jakéhokoliv množství xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx krve xxxx produktů z xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.

XXXXXXXX

Xxxxxxxx xxxx nebo xxxxxxxx xxxxxx, včetně xxxxxxx, xxxx zakázáno xxx provádění x xxxxxxxxx xxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx xxxx, xx xxxxx xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, xxxxxxx xxxx xxxxxxx kyslíku.

Mimo xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx x modifikované xxxxxxxxxxxxx produkty, xxxx. xxxxxx náhražky xx xxxx xxxxxxxxxxx x xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x výjimkou xxxxxxxxxxx xxxxxxx inhalací.

M1.3. Xxxxxxxxx xxxxx intravaskulární xxxxxxxxxx x krví xxxx x krevními xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX MANIPULACE

Zakázáno xx xxxxxxxxxxx:

X2.1. Xxxxxxxxx xxxx Xxxxx x xxxxxx xx účelem porušit xxxxxxxxx x platnost Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Xxxxxx.

X2.2. Xxxxxxxxxx xxxxxx a/nebo xxxxxxx více xxx xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx v xxxxxxx xxxxxxxxxxxx ošetření, xxxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxxx vyšetření.

M3. XXXXXX X XXXXXXX XXXXXX

X xxxxxx potencionálního xxxxxxx xxxxxxxxxxx xxxxxx je xxxxxxxx xxxxxxxxxxx:

X3.1. Xxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx analogů, které xxxxx xxxxxx sekvence xxxxxx a/nebo xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx xxxx jiné xxxxxxxx xxxxxxxxxxx xxxxx xxxx, umlčování xxxx x xxxxxxxxxxx xxxxxxx xxxx.

X3.2. Xxxxxxx normálních xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X6 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Specifické látky x xxxxxxxx xxxxx xxxxxxxxx v X6.X, xxx jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxx látky x xxxx xxxxx: kokain x xxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“)

Xxxxxxx xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, např. x- x l-, xxxx xxxxxxxx.

Xxxxxxxxxxx zahrnují:

S6.A: XXXXXXXXXXXX STIMULANCIA

•	adrafinil		•	fonturacetam [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx (fluorenol)
•	amfetaminil		•	lisdexamfetamin
•	amifenazol		•	mefenorex
•	benfluorex		•	mefentermin
•	benzylpiperazin		•	mezokarb
•	bromantan		•	metamfetamin(d-)
•	klobenzorex		•	p-metylamfetamin
•	kokain		•	modafinil
•	kropropamid		•	norfenfluramin
•	krotetamid		•	fendimetrazin
•	fenkamin		•	fentermin
•	fenetylin		•	prenylamin
•	fenfluramin		•	prolintan
•	fenproporex

Stimulans, xxxxx xxxx xxxxxxxx xxxxxx x xxxxx oddíle, xx Xxxxxxxxxxx xxxxxx.

X6.X: XXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, BMPEA)		•	famprofazon		•	oktopamin
•	3-metylhexan-2-amin (1,2-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx		•	xxxxxxxxx (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 DMAA, metylhexanamin)		•	heptaminol		•	pentetrazol
•	4-methylpentan-2-amin (1,3-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxxxxxx (parahydroxyamfetamin)		•	fenetylamin x xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxx1)		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxx a xxxx analogy, xxxx. xxxxxxxx, metedron x ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxx3)		•	xxxxxxxxx
•	xxxxxxx3)		•	xxxxxxxxxxxxx [(±)-metyl-2-(naftalen-2-yl)-2-(piperidin-2- xx)xxxxxx]		•	xxxxxxxxxx
•	xxxxxxxxx (xxxxxxxxx)4)		•	xxxxxxxxxxxx		•	xxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx (metylendioxyamfetamin)
•	etylamfetamin		•	norfenefrin		•	tesofensin
•	etilefrin		•	oktodrin (1,5-xxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxxx

x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx

XXXXXXX

• xxxxxxxx; xxxxxxxxx;

• xxxxxxxx imidazolinu xxx xxxxxxxxxxxxxx, xxxxx, xxxx nebo xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, tetryzolin, xxxxxxxxxx, xxxxxxxxxxxxx) a xxxxxxxxxxx zařazená xx Xxxxxxxxxxxxxx xxxxxxxx 2025⁵⁾.

X7 XXXXXXXXX

XXXXXXXX XXX SOUTĚŽI

Všechny xxxxxxxx látky v xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x této xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx narkotika, xxxxxx jejich xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx x xxxx xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (xxxxxx)		•	xxxxxxx		•	xxxxxxxx		•	xxxxxxxx
						•	xxxxxxxxx

X8 KANABINOIDY

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx xxxxxxxx látky x této xxxxx xxxx Specifické xxxxx. Xxxxxxxx xxxxx x xxxx sekci: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx a xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx, xxxx.

• v xxxxxx (xxxxx, xxxxxxxxx) x konopných produktech

• xxxxxxxx x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxx (XXX)

• syntetické xxxxxxxxxxx napodobující xxxxxx XXX

XXXXXXX

• xxxxxxxxxx

X9 GLUKOKORTIKOIDY

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx v této xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, pokud xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx oromukózní (xxxx. bukální, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Xxxx xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) xxxxxx xxxxxxxx, xxxxx xx xxxxxxxxx v xxxxx xxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxx.

X1 XXXX-XXXXXXXXX

XXXXXXXX X XXXXXXXX SPORTECH

Všechny zakázané xxxxx v této xxxxx xxxx Specifické xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx v xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx x xxx xx xx xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.

•	xxxxxxxxxxx (WA)*		•	Podvodní xxxxxx (XXXX)* v xxxxxxxxxxxx xxxxxxx potápění, lovu xxxxxxxx a xxxxxxx xx xxxx
•	xxxxxxxxxxxx sport (XXX)
•	xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
•	xxxxx (XXX)
•	xxxx (XXX)
•	xxxxxxxx (XXX)
•	xxxxxxx (XXXX, XXX)*

* xxxxxxxx xxxx Mimo xxxxxx

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx l-izomer: je xxxxxxxx pouze xxx xxxxxxxxxxx v xxxx xxxxx než 5 xxxxxxxxxx v 1 xx.

²⁾ xxxxxxxxxxxxx: xxxxxxxx xxxxx xxx koncentraci x xxxx xxxxx xxx 150 xxxxxxxxxx x 1 ml.

³⁾ xxxxxxx x metylefedrin: xxxxxxxx xxx koncentraci x xxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx.

⁴⁾ xxxxxxxxx (xxxxxxxxx): není xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxx, xxxx, xxxx xxxxxxxx xxxxxxxx x lokálními anestetiky.

⁵⁾ xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: tyto xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2025 x xxxxxx xxxxxxxxxx za Xxxxxxxx xxxxx.

Informace

Právní předpis x. 163/2026 Xx. xxxxx xxxxxxxxx xxxx 15.9.2026.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů x odkazech xxxx xxxxxxxxxxxxx, xxxxx se xxxx netýká xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.